Fiduciary Management Inc. WI Sells 79,942 Shares of Icon Plc $ICLR

Fiduciary Management Inc. WI trimmed its stake in shares of Icon Plc (NASDAQ:ICLR) by 14.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 480,996 shares of the medical research company’s stock after selling 79,942 shares during the quarter. Fiduciary Management Inc. WI’s holdings in Icon were worth $87,647,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Toth Financial Advisory Corp acquired a new position in Icon in the 4th quarter valued at approximately $27,000. Ameriflex Group Inc. acquired a new position in Icon in the 3rd quarter valued at approximately $33,000. Johnson Financial Group Inc. acquired a new stake in shares of Icon during the third quarter worth $71,000. Quadrant Capital Group LLC acquired a new stake in shares of Icon during the third quarter worth $78,000. Finally, Geneos Wealth Management Inc. boosted its stake in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ICLR. BMO Capital Markets raised their price objective on shares of Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research note on Friday, May 29th. TD Cowen raised their price target on shares of Icon from $120.00 to $164.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Citigroup raised their price target on shares of Icon from $120.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, May 29th. Barclays raised their price target on shares of Icon from $120.00 to $150.00 and gave the company an “equal weight” rating in a research report on Friday, May 29th. Finally, Piper Sandler lowered shares of Icon to a “neutral” rating in a research report on Thursday, May 28th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $156.44.

Icon Price Performance

ICLR stock opened at $149.45 on Friday. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00. The firm has a market capitalization of $12.07 billion, a P/E ratio of 24.26, a price-to-earnings-growth ratio of 10.13 and a beta of 1.26. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.31. The firm has a 50 day moving average of $117.51 and a 200-day moving average of $140.85.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share (EPS) for the quarter. The business had revenue of $2.11 billion during the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. As a group, sell-side analysts predict that Icon Plc will post 9.74 earnings per share for the current fiscal year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.